Liquid Biopsy in Paraneoplastic Neurological Syndromes
Liquid Biopsy in Paraneoplastic Neurological Syndromes With High- and Intermediate-Risk Antibodies
Heinrich-Heine University, Duesseldorf
60 participants
May 20, 2023
OBSERVATIONAL
Conditions
Summary
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
Eligibility
Inclusion Criteria2
- Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies or
- Patients with peripheral tumors without PNS
Exclusion Criteria3
- Age below 18 years at the time of inclusion.
- Any mental condition impairing the capacity to provide informed consent.
- Presence of contraindications to DLA.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07491328